.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Dow
Citi
Farmers Insurance
AstraZeneca
Deloitte
Chubb
Cantor Fitzgerald
Express Scripts
Medtronic
Chinese Patent Office

Generated: September 21, 2017

DrugPatentWatch Database Preview

Details for Patent: ► Subscribe

« Back to Dashboard

Which drugs does patent 8,371,292 protect, and when does it expire?


Patent ► Subscribe protects OMNARIS, ZETONNA, and ALVESCO, and is included in three NDAs. There has been one Paragraph IV challenge on Omnaris.

This patent has ten patent family members in eleven countries.

Summary for Patent: ► Subscribe

Title:Use of ciclesonide for the treatment of respiratory diseases
Abstract: The invention relates to new method of treatment of respiratory diseases, in particular the treatment of asthmatic children.
Inventor(s): Bethke; Thomas (Constance, DE), Engelstaetter; Renate (Allensbach, DE), Wurst; Wilhelm (Constance, DE)
Assignee: Nycomed GmbH (Constance, DE)
Application Number:10/571,311
Patent Claim Types:
see list of patent claims
Use; Composition; Formulation; Dosage form; Delivery;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Astrazeneca Pharms
OMNARIS
ciclesonide
SPRAY, METERED;NASAL022004-001Oct 20, 2006RXYesYes► Subscribe► Subscribe TREATMENT OF NASAL SYMPTOMS ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS IN ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER. TREATMENT OF NASAL SYMPTOMS ASSOCIATED W PERENNIAL ALLERGIC RHINITIS IN ADULTS AND ADOLESCENTS 12 YEARS OF AGE AND OLDER
Astrazeneca Pharms
ZETONNA
ciclesonide
AEROSOL, METERED;NASAL202129-001Jan 20, 2012RXYesYes► Subscribe► Subscribe TREATMENT OF SYMPTOMS ASSOCIATED WITH SEASONAL AND PERENNIAL ALLERGIC RHINITIS IN ADULTS AND ADOLESCENTS 12 YEARS OF AGE AND OLDER. PATENT CLAIMS METHODS FOR TREATING A RESPIRATORY DISEASE IN A CHILD
Astrazeneca Pharms
ALVESCO
ciclesonide
AEROSOL, METERED;INHALATION021658-002Jan 10, 2008RXYesYes► Subscribe► Subscribe MAINTENANCE TREATMENT OF ASTHMA AS PROPHYLACTIC THERAPY IN ADULT AND ADOLESCENT PATIENTS 12 YEARS OF AGE AND OLDER. PATENT CLAIMS METHOD FOR TREATING A RESPIRATORY DISEASE IN A CHILD
Astrazeneca Pharms
ALVESCO
ciclesonide
AEROSOL, METERED;INHALATION021658-003Jan 10, 2008RXYesYes► Subscribe► Subscribe MAINTENANCE TREATMENT OF ASTHMA AS PROPHYLACTIC THERAPY IN ADULT AND ADOLESCENT PATIENTS 12 YEARS OF AGE AND OLDER. PATENT CLAIMS METHOD FOR TREATING A RESPIRATORY DISEASE IN A CHILD
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: ► Subscribe

PCT Information
PCT FiledSeptember 15, 2004PCT Application Number:PCT/EP2004/052172
PCT Publication Date:March 24, 2005PCT Publication Number: WO2005/025578

International Patent Family for Patent: ► Subscribe

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia2004271744► Subscribe
Canada2538419► Subscribe
Cyprus1117371► Subscribe
Denmark1670482► Subscribe
European Patent Office1670482► Subscribe
Spain2452691► Subscribe
CroatiaP20140257► Subscribe
Japan2007505829► Subscribe
Japan2012197306► Subscribe
Japan5618452► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Johnson and Johnson
US Department of Justice
Teva
Merck
Chubb
Fuji
Daiichi Sankyo
Julphar
Argus Health
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot